Page last updated: 2024-08-22

vidarabine and Demyelinating Diseases

vidarabine has been researched along with Demyelinating Diseases in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19901 (25.00)18.7374
1990's1 (25.00)18.2507
2000's1 (25.00)29.6817
2010's0 (0.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Bejar, J; Garty-Ofir, M; Kreiniz, N; Polliack, A; Tadmor, T1
Bertz, H; Bley, TA; Feuerhake, F; Finke, J; Mielke, S; Potthoff, K; Windfuhr, M1
Johnson, RT1
Bolgert, F; Camporo, P; Gonzalez, H; Leblond, V1

Other Studies

4 other study(ies) available for vidarabine and Demyelinating Diseases

ArticleYear
Demyelinating brain lesions developing in a patient with chronic lymphocytic leukemia shortly after treatment with a fludarabine containing regimen.
    Hematological oncology, 2021, Volume: 39, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Edema; Cyclophosphamide; Demyelinating Diseases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Steroids; Vidarabine

2021
Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation.
    Onkologie, 2007, Volume: 30, Issue:1-2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclosporine; Demyelinating Diseases; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Assessment; Stem Cell Transplantation; Vidarabine

2007
Current concepts in neurology: the contribution of virologic research to clinical neurology.
    The New England journal of medicine, 1982, Sep-09, Volume: 307, Issue:11

    Topics: Acyclovir; Animals; Antiviral Agents; Creutzfeldt-Jakob Syndrome; Demyelinating Diseases; Encephalitis; Encephalomyelitis; Guanine; Herpes Simplex; Humans; Nervous System Diseases; Polyradiculoneuropathy; Reye Syndrome; Vidarabine; Virus Diseases

1982
Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP).
    Hematology and cell therapy, 1999, Volume: 41, Issue:4

    Topics: Antineoplastic Agents; Demyelinating Diseases; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Neurotoxicity Syndromes; Vidarabine

1999